Answers are grounded in this paper and cite their sources.
Not only does the microenvironment influence metastases, but metastases also influence their microenvironment. However, in the case of dural metastases (DM), their effects on the meninges and surrounding areas remain poorly understood. Zeng, Zhao, Peng, and colleagues sought to address this by first characterizing high-resolution computed tomography scans from patients with DM. Interestingly, a distinct pattern of tumor-adjacent skull thinning was observed in each case of DM, but not in other central nervous system metastases or benign meningiomas. These results were also recapitulated in the 4T1-DM mouse model, which was developed in this study to reliably establish dural metastases from a syngeneic murine breast cancer cell line. In this system, skull thinning was accompanied by dilation, blebbing, and injury of the meningeal lymphatic vessels (MLV), visualized by LYVE1+ immunofluorescence. Drainage of cerebrospinal fluid (CSF) containing fluorescent tracers (FITC-dextran, OVA-AF488) was also impaired in 4T1-DM mice, providing further evidence of DM-dependent MLV dysfunction. Single-cell RNA sequencing of dural cells from both tumor-bearing and non-tumor control animals revealed two DM-specific signatures: the emergence of an osteoclast (OC) population and pronounced T-cell exhaustion. To investigate the functional consequences of this OC population, 4T1-DM mice were treated with either vehicle or zoledronic acid (ZOL), a functional OC inhibitor. ZOL treatment was sufficient to rescue both structural and functional MLV integrity in vivo, with more normalized LYVE1+ MLV architecture and improved drainage of fluorescent tracers to deep cervical lymph nodes. Importantly, ZOL treatment markedly reduced tumor burden and improved survival of 4T1-DM mice. CD8+ T cells were also more abundant in ZOL-treated animals, with diminished expression of exhaustion markers (PD-1, TIM3) quantified using flow cytometry. Coadministration of ZOL and an anti-CD8 neutralizing antibody effectively reversed the antitumor effects of ZOL alone in the 4T1-DM model, which suggests that OCs exacerbate DM progression by driving localized immunosuppression. Further mechanistic studies revealed that this process is influenced by OC-derived angiopoietin-2 (ANG2), as cotreatment with recombinant ANG2 restored MLV dysfunction phenotypes, CD8+ T-cell exhaustion, and tumor progression in ZOL-treated 4T1-DM models. Taken together, this study indicates that OCs may play an active, targetable role in mediating lymphatic remodeling and antitumor immune responses in DM.Zeng R, Zhao J, Peng H, Ma J, Hua S, Zeng Y, et al. Osteoclasts intercept meningeal lymphatic paths for dural metastasis. Nature 2026;658:1025–35.Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at https://aacrjournals.org/cdnews.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: